The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation ...

Sobi® (STO: SOBI) together with the World Federation of Hemophilia (WFH) and Sanofi, through its philanthropic organisation Foundation S, announced the signing of a contract providing support to the ...

Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistanceSTOCKHOLM, April 25, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) together ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of treatment administered every two months for patients with the rare blood clotting ...

Sanofi’s Foundation S & Sobi extend partnership with the World Federation of Haemophilia Humanitarian Aid Programme: Paris Saturday, April 26, 2025, 09:00 Hrs [IST] Sanofi, thro ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. Into this crowded treatment landscape comes another new medicine as the FDA has signed off ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US Food and Drug Administration, offering patients greater choice as the ...

Sanofi's Qfitlia, approved a few days ago by the FDA, offers a competitive edge in the hemophilia market with fewer injections and broader applicability than rivals. Despite Qfitlia's promising ...